Relay Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Relay Therapeutics Inc RLAY.OQ reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -69 cents. The mean expectation of eleven analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -57 cents to -37 cents per share.

• Revenue was $677.00 thousand​; analysts expected $60.00 thousand.

• Relay Therapeutics Inc's reported EPS for the quarter was a loss of 41 cents​.

• The company reported a quarterly loss of $70.38 million.

• Relay Therapeutics Inc shares had risen by 2.0% this quarter and lost 14.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Relay Therapeutics Inc is $14.00, about 75.1% above its last closing price of $3.49

This summary was machine generated from LSEG data August 8 at 03:15 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)